Prosecution Insights
Last updated: April 19, 2026

Examiner: CORDAS, EMILY ANN

Tech Center 1600 • Art Units: 1632 1651 1683

This examiner grants 50% of resolved cases

Performance Statistics

50.4%
Allow Rate
-9.6% vs TC avg
588
Total Applications
+58.4%
Interview Lift
1350
Avg Prosecution Days
Based on 534 resolved cases, 2023–2026

Rejection Statute Breakdown

4.4%
§101 Eligibility
18.2%
§102 Novelty
40.1%
§103 Obviousness
28.2%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
17919677 CLEARANCE OF SENESCENT CELLS BY ACTIVATION OF iNKT CELLS Non-Final OA THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
17799851 Regulating Activation of Fibroblasts to Prevent Fibrosis Non-Final OA The Regents of the University of California
16840173 TREATING ROTATOR CUFF CONDITIONS Final Rejection Mayo Foundation for Medical Education and Research
16149538 SYSTEMS AND METHODS FOR RETURNING TREATED MONONUCLEAR CELLS TO A BLOOD SOURCE Final Rejection Fenwal, Inc.
17180506 System and Method for Organ Maintenance and Transport Final Rejection DEKA Products Limited Partnership
17838428 MODULATION OF UBIQUITIN CARBOXY-TERMINAL HYDROLASE LIGASE 1 (UCHL1) EXPRESSION FOR TREATING NEUROLOGICAL DISEASE, DISORDERS, AND INJURIES ASSOCIATED WITH UPPER MOTOR NEURONS Final Rejection Northwestern University
18009231 METHOD OF MANUFACTURING MICRODEVICES FOR LAB-ON-CHIP APPLICATIONS Non-Final OA Wageningen Universiteit
19208449 BIOLOGICAL TISSUE AND METHOD OF MANUFACTURING Final Rejection BioCreations Medical, LLC
19194137 USE OF HUMAN UMBILICAL CORD MESENCHYMAL STEM CELL-DERIVED EXOSOMES (hUC-MSC-ES) Final Rejection BEIJINGANZHEN HOSPITAL,CAPITALMEDICAL UNIVERSITY
18022234 Materials for Tumor Inoculation in Murine Mouse Models and Uses Thereof Non-Final OA The Board of Trustees of the Leland Stanford Junior University
18025036 Complex Containing Neural Retina-Containing Cell Aggregates and Matrix, and Method for Manufacturing Same Non-Final OA Sumitomo Pharma Co., Ltd.
17611500 TREATMENT OF ISCHEMIC STROKE WITH APTAMERS TARGETING TLR-4 Non-Final OA Merck Patent GmbH
17407604 Cardiac Muscle-Cell-Based Coupled Oscillator Network for Collective Computing and Related Methods Final Rejection University of Virginia Patent Foundation
17777460 COMPOSITION, COMPRISING COTL1 AS ACTIVE INGREDIENT, FOR DIAGNOSIS OF BONE DISEASE OR OBESITY Non-Final OA AJOU UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION
17668332 FIBROUS POLYMERIC SCAFFOLDS FOR SOFT TISSUE ENGINEERING Non-Final OA The Trustees of Columbia University in the City of New York
18024091 METHODS FOR REPROGRAMMING TARGET CELLS Non-Final OA Duke University
17959327 CANNABIDIOL-CONTAINING COMPOSITIONS AND USES THEREOF Non-Final OA Ramot at Tel-Aviv University Ltd.
17053422 STEM CELL-DERIVED CELL CULTURES, STEM CELL-DERIVED THREE DIMENSIONAL TISSUE PRODUCTS, AND METHODS OF MAKING AND USING THE SAME Non-Final OA The Regents of the University of Colorado, A Body Corporate
18000706 ENCODING AND EXPRESSION OF ACE-tRNAs Non-Final OA University of Rochester
18021596 3D NEURONAL TISSUE GRAFTS USING ULTRASHORT SELF-ASSEMBLING PEPTIDE SCAFOLDS Non-Final OA KING ABDULLAH UNIVERSITY OF SCIENCE AND TECHNOLOGY
18133237 MEDIA COMPOSITIONS FOR NEURONAL CELL CULTURE Final Rejection SALK INSTITUTE FOR BIOLOGICAL STUDIES
18533611 METHOD FOR CULTURING 3-DIMENSIONAL LUNG CANCER ORGANOID AND METHOD FOR PREPARING PATIENT-DERIVED XENOGRAFT ANIMAL MODEL USING SAME Non-Final OA SG MEDICAL, INC.
17260754 IMPLANTS TO INDUCE BONE REGENERATION AND USES THEREOF Non-Final OA University of lowa Research Foundation
18371694 APPARATUS AND METHOD FOR INDUCING HUMAN OOCYTE MATURATION IN VITRO Final Rejection Gameto, Inc.
17922119 COMPOSITIONS AND METHODS FOR TREATMENT OF INHERITED MACULAR DEGENERATION Non-Final OA Blue Marlin Therapeutics, Inc.
16970888 COMPOSITIONS AND METHODS FOR ORGAN-PROTECTIVE EXPRESSION AND MODULATION OF CODING RIBONUCLEIC ACIDS Non-Final OA Combined Therapeutics, Inc.
17816998 COMPOSITION FOR BONE REGENERATION CONTAINING HYDROGEL AND STEM CELL SPHEROID, AND USE THEREOF Final Rejection SELJIN CO.LTD.
17846391 SCAFFOLDS TO TREAT SOLID TUMOR CELLS AND ESCAPE VARIANTS Non-Final OA Monarch Biosciences, Inc.
17745016 CELLULAR TARGETED PHARMACEUTICALLY ACTIVE SUBSTANCE OR LABEL DELIVERY SYSTEM Final Rejection CELLIS AG
16068096 CELLULAR BLEND FOR THE REGENERATION OF CHONDROCYTES OR CARTILAGE TYPE CELLS Non-Final OA SpinalCyte, LLC

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month